Anavex Life Sciences Corp (AVXL)

[nidan7500]

RESEARCH IN CONTEXT

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167374/

Systematic review: The authors reviewed the literature using PubMed, clinicaltrials.gov, and relevant Alzheimer's disease (AD) meeting abstracts and presentations. This study is, to the best of our knowledge, the first reported genome-wide search for biomarkers associated with drug response in AD.
Interpretation of results: Our findings have led to the identification of two genomic variants and a clinical baseline to pre-specify patients most likely to respond to a SIGMAR1 therapy using blarcamesine.

Future directions: The findings from this analysis have led to an ongoing confirmatory, randomized, and placebo-controlled Phase 2b/3 study investigating blarcamesine in 450 subjects (NCT03790709).

SO WHAT YOU SAY?

My simple minded assessment is, they think they have identified which AD patients will/will not respond positively to A2-73 and how they will respond-measure/track/manage them . If I have that correct, it is a massively important accomplishment in many ways. The trial has been planned (NCT03790709), scheduled. Stay tuned. At least we feel a little better now. My problem is the timing is too far out. Now, all the increased emphasis on PDD and RSD strategy makes more sense. So, now the PDD trial just got a lot bigger for me. Now looks like Dr.M. had to replan b/c the HH AI data introduced big changes in study-trial planning. Still not happy w/long wait but understand why. Partnership of some kind seems more likely to me now that I see a different picture.

Some of the blocks are beginning to fit, just wish I had a time machine to fast forward.